2162-3619

Experimental Hematology and Oncology

Springer (Biomed Central Ltd.)

View prefix report (10.1186)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 747 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact747 DOIs
2

Add abstracts to 292 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact292 DOIs
3

Add license metadata to 146 records

License metadata tells indexers and readers how each article may be reused.

Low impact146 DOIs

DOIs for this ISSN

Showing the top 5 of 911 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Breast cancer brain metastases: the last frontier (10.1186/s40164-015-0028-8)
Abstract ORCID License
162.33 145
2 Childhood B-acute lymphoblastic leukemia: a genetic update (10.1186/2162-3619-3-16)
Abstract ORCID License
150.96 102
3 The development of bispecific antibodies and their applicati… (10.1186/s40164-017-0072-7)
Abstract ORCID License
149.01 96
4 Development and clinical application of anti-HER2 monoclonal… (10.1186/s40164-017-0091-4)
Abstract ORCID License
147.28 91
5 Metaplastic breast cancer: histologic characteristics, progn… (10.1186/2162-3619-2-31)
Abstract ORCID License
144.32 83
6 GATA family transcriptional factors: emerging suspects in he… (10.1186/s40164-015-0024-z)
Abstract ORCID License
139.75 72
7 Ibrutinib for B cell malignancies (10.1186/2162-3619-3-4)
Abstract ORCID License
138.84 70
8 Advances of CD19-directed chimeric antigen receptor-modified… (10.1186/s40164-017-0070-9)
Abstract ORCID License
137.44 67
9 Pivotal regulators of tissue homeostasis and cancer: macroph… (10.1186/s40164-017-0083-4)
Abstract ORCID License
135.46 63
10 CD19: a biomarker for B cell development, lymphoma diagnosis… (10.1186/2162-3619-1-36)
ORCID License
135.29 507
11 Altered expression pattern of miR-29a, miR-29b and the targe… (10.1186/2162-3619-3-17)
Abstract ORCID License
132.81 58
12 Thalidomide and its analogues in the treatment of Multiple M… (10.1186/2162-3619-1-27)
Abstract ORCID License
130.53 54
13 Cohesin mutations in myeloid malignancies: underlying mechan… (10.1186/2162-3619-3-13)
Abstract ORCID License
127.42 49
14 Successful treatment of a Caucasian case of multifocal Castl… (10.1186/2162-3619-4-3)
Abstract ORCID License
127.42 49
15 Long noncoding RNAs: pivotal regulators in acute myeloid leu… (10.1186/s40164-016-0059-9)
Abstract ORCID License
126.76 48
16 A randomized exploratory phase 2 study in patients with chem… (10.1186/s40164-017-0065-6)
Abstract ORCID License
126.76 48
17 Tumor dormancy: potential therapeutic target in tumor recurr… (10.1186/2162-3619-2-29)
Abstract ORCID License
125.41 46
18 Gemcitabine plus nab-paclitaxel for advanced pancreatic canc… (10.1186/s40164-015-0025-y)
Abstract ORCID License
123.99 44
19 Phenethyl isothiocyanate and paclitaxel synergistically enha… (10.1186/2162-3619-3-5)
Abstract ORCID License
122.51 42
20 Neuroblastoma of the elderly, an oncologist’s nightmare: cas… (10.1186/2162-3619-3-20)
Abstract ORCID License
121.74 41
21 miR-199b, a novel tumor suppressor miRNA in acute myeloid le… (10.1186/s40164-016-0033-6)
Abstract ORCID License
121.74 41
22 The effect of caffeine on cisplatin-induced apoptosis of lun… (10.1186/2162-3619-4-5)
Abstract ORCID License
120.96 40
23 Comparison of safety and toxicity of liposomal doxorubicin v… (10.1186/2162-3619-1-10)
ORCID License
120.92 261
24 CD133: a stem cell biomarker and beyond (10.1186/2162-3619-2-17)
Abstract ORCID
120.66 258
25 Tissue factor-dependent and -independent pathways of systemi… (10.1186/s40164-015-0018-x)
Abstract ORCID License
120.15 39
26 ABC transporter activity linked to radiation resistance and… (10.1186/2162-3619-2-26)
Abstract ORCID License
119.33 38
27 The role of cullin4B in human cancers (10.1186/s40164-017-0077-2)
Abstract ORCID License
117.62 36
28 The use of erythropoiesis-stimulating agents with ruxolitini… (10.1186/s40164-015-0021-2)
Abstract ORCID License
116.72 35
29 Novel agents and strategies for overcoming EGFR TKIs resista… (10.1186/2162-3619-3-2)
Abstract ORCID License
113.89 32
30 Distinct genetic alterations in small cell carcinoma from di… (10.1186/2162-3619-4-2)
Abstract ORCID License
113.89 32
31 Radium-223 dichloride bone-targeted alpha particle therapy f… (10.1186/2162-3619-3-23)
Abstract ORCID License
112.89 31
32 Mechanisms for estrogen receptor expression in human cancer (10.1186/s40164-018-0116-7)
Abstract ORCID
112.64 178
33 nab-Paclitaxel for the treatment of breast cancer: an update… (10.1186/s40164-017-0066-5)
Abstract ORCID License
111.85 30
34 Organoid technology in disease modelling, drug development,… (10.1186/s40164-018-0122-9)
Abstract ORCID
111.39 168
35 Everolimus and sunitinib for advanced pancreatic neuroendocr… (10.1186/2162-3619-2-32)
Abstract ORCID License
110.78 29
36 Survival and hospitalization among patients with acute myelo… (10.1186/2162-3619-3-10)
Abstract ORCID License
109.68 28
37 Analysis of the anti-proliferative and the pro-apoptotic eff… (10.1186/s40164-015-0016-z)
Abstract ORCID License
109.68 28
38 Single low-dose rHuIL-12 safely triggers multilineage hemato… (10.1186/2162-3619-3-11)
Abstract ORCID License
108.54 27
39 A systematic classification of megakaryocytic dysplasia and… (10.1186/s40164-016-0041-6)
Abstract ORCID License
106.12 25
40 Patterns of hydroxyurea use and clinical outcomes among pati… (10.1186/s40164-016-0031-8)
Abstract ORCID License
104.85 24
41 Incorporation of functional elements enhances the antitumor… (10.1186/s40164-017-0088-z)
Abstract ORCID License
104.85 24
42 The effect of metronomic versus standard chemotherapy on the… (10.1186/2162-3619-3-3)
Abstract ORCID License
103.52 23
43 Novel antidotes for target specific oral anticoagulants (10.1186/s40164-015-0020-3)
Abstract ORCID License
103.52 23
44 The role of neoantigen in immune checkpoint blockade therapy (10.1186/s40164-018-0120-y)
Abstract ORCID
102.85 113
45 Cancer immunotherapy: are we there yet? (10.1186/2162-3619-2-33)
Abstract ORCID License
102.13 22
46 Digitoxin and its analogs as novel cancer therapeutics (10.1186/2162-3619-1-4)
ORCID License
101.87 108
47 Diagnostic and therapeutic challenges of EBV-positive mucocu… (10.1186/s40164-016-0042-5)
Abstract ORCID
101.06 104
48 The combination of dendritic cells-cytotoxic T lymphocytes/c… (10.1186/s40164-015-0027-9)
Abstract ORCID License
100.68 21
49 New CD20 alternative splice variants: molecular identificati… (10.1186/s40164-016-0036-3)
Abstract ORCID License
100.68 21
50 Emerging therapies in advanced hepatocellular carcinoma (10.1186/s40164-018-0109-6)
Abstract ORCID
100.43 101